Matrix metalloproteinases and atherosclerosis: Review;Matriks metalloproteinaz enzimleri ve ateroskleroz

Turkiye Klinikleri Journal of Medical Sciences

Volumn 26, Issue 5, 2006, Pages 527-537

  Reel, Buket ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Atherosclerosis; Extracellular matrix; Matrix metalloproteinase

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; 4 [[[4 (4 CHLOROPHENOXY)PHENYL]SULFONYL]METHYL]TETRAHYDRO 2H PYRAN 4 CARBOHYDROXAMIC ACID; 5 ETHOXYMETHOXY N HYDROXY 2 METHYL 4 (4 PHENOXYBENZAMIDO)PENTANAMIDE; AE 941; BATIMASTAT; CGS 27023A; CIPEMASTAT; CP 471358; CPA 926; DOXYCYCLINE HYCLATE; MARIMASTAT; MATRIX METALLOPROTEINASE; PRINOMASTAT; REBIMASTAT; RO 323555; S 3304; TANOMASTAT; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; ENZYME ACTIVITY; GENETIC TRANSCRIPTION; PATHOGENESIS; REVIEW;

EID: 33751226265     PISSN: 13000292     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Libby P, Lee RT. Matrix matters. Circulation 2000;102:1874-6.
2. th ed. New York: W.H. Freeman and Company; 1999. p.968-93.
3. Massova I, Kotra LP, Fridman R, Mobashery S. Matrix metalloproteinases: Structures, evolution, and diversification. FASEB J 1998;12:1075-95.
4. Jacob MP. Extracellular matrix remodeling and matrix metalloproteinases in the vascular wall during aging and in pathological conditions. Biomed Pharmacother 2003;57:195-202.
5. Jacob MP, Badier-Commander C, Fontaine V, Benazzoug Y, Feldman L, Michel, JB. Extracellular matrix remodeling in the vascular wall. Pathol Biol 2001;49:326-32.
6. Garcia-Touchard A, Henry TD, Sangiorgi G, et al. Extracellular proteases in atherosclerosis and restenosis. Arterioscler Thromb Vasc Biol 2005;25:1119-27.
7. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: The good, the bad, and the ugly. Circ Res 2002;90:251-62.
8. Nagase H, Woessner JFJr. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4.
9. Lambert E, Dasse E, Haye B, Petitfrere E. TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004;49:187-98.
10. Beaudeux JL, Giral P, Bruckert E, Foglietti MJ, Chapman MJ. Matrix metalloproteinases, inflammation and atherosclerosis: Therapeutic perspectives. Clin Chem Lab Med 2004;42:121-31.
11. Hoekstra R, Eskens FA, Verweij J. Matrix metalloproteinase inhibitors: Current developments and future perspectives. Oncologist 2001;6:415-27.
12. Jones CB, Sane DC, Herrington DM. Matrix metalloproteinases: A review of their structure and role in acute coronary syndrome. Cardiovasc Res 2003;59:812-23.
13. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463-516.
14. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ Res 2003;92:827-39.
15. Kuzuya M, Iguchi A. Role of matrix metalloproteinases in vascular remodeling. J Atheroscler Thromb 2003;10:275-82.
16. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995;77:863-8.
17. Mook OR, Frederiks WM, Van Noorden CJ. The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 2004;1705:69-89.
18. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets. Int J Cancer 2002;99:157-66.
19. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 1997;378:151-60.
20. Murphy G, Willenbrock F, Crabbe T, et al. Regulation of matrix metalloproteinase activity. Ann NY Acad Sci 1994;732:31-41.
21. Rosano L, Salani D, Di Castro V, Spinella F, Natali PG, Bagnato A. Endothelin-1 promotes proteolytic activity of ovarian carcinoma. Clin Sci 2002;103(Suppl 48):306-9.
22. McCawley LJ, Li S, Benavidez M, Halbleib J, Wattenberg EV, Hudson LG. Elevation of intracellular cAMP inhibits growth factor-mediated matrix metalloproteinase-9 induction and keratinocyte migration. Mol Pharmacol 2000;58:145-51.
23. More RS, Underwood MJ, Brack MJ, de Bono DP, Gershlick AH. Changes in vessel wall plasminogen activator activity and smooth muscle cell proliferation and activation after arterial injury. Cardiovasc Res 1995;29:22-6.
24. Estreicher A, Wohlwend A, Belin D, Schleuning WD, Vassalli JD. Characterization of the cellular binding site for the urokinase-type plasminogen activator. J Biol Chem 1989;264:1180-9.
25. Carmeliet P, Moons L, Lijnen R, et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 1997;17:439-44.
26. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993;91:2546-51.
27. Borkakoti N. Matrix metalloprotease inhibitors: Design from structure. Biochem Soc Trans 2004;32(Pt 1):17-20.
28. Peterson JT. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev 2004;9:63-79.
29. Loftus IM, Thompson MM. The role of matrix metalloproteinases in vascular disease. Vasc Med 2002;7:117-33.
30. Axisa B, Loftus IM, Naylor AR, et al. Prospective, randomized, double-blind trial investigating the effect of doxycycline on matrix metalloproteinase expression within atherosclerotic carotid plaques. Stroke 2002;33:2858-64.
31. Zempo N, Koyama N, Kenagy RD, Lea HJ, Clowes AW. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler Thromb Vasc Biol 1996;16:28-33.
32. McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Clinical review 145: Pleiotropic effects of statins: Lipid reduction and beyond. J Clin Endocrinol Metab 2002;87:1451-8.
33. Porter KE, Turner NA. Statins for the prevention of vein graft stenosis: A role for inhibition of matrix metalloproteinase-9. Biochem Soc Trans 2002;30:120-6.
34. Suzuki H, Kobayashi H, Sato F, Yonemitsu Y, Nakashima Y, Sueishi K. Plaque-stabilizing effect of pitavastatin in Watanabe heritable hyperlipidemic (WHHL) rabbits. J Atheroscler Thromb 2003;10:109-16.
35. Cipollone F, Fazia M, Iezzi A, et al. Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation 2003;107:1479-85.
36. Rosano L, Spinella F, Salani D, et al. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. Cancer Res 2003;63:2447-53.
37. Cho A, Graves J, Reidy MA. Mitogen-activated protein kinases mediate matrix metalloproteinase-9 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000;20:2527-32.
38. Rajavashisth TB, Liao JK, Galis ZS, et al. Inflammatory cytokines and oxidized low density lipoproteinsincrease endothelial cell expression of membrane type 1-matrix metalloproteinase. J Biol Chem 1999;274:11924-9.
39. Zaltsman AB, Newby AC. Increased secretion of gelatinases A and B from the aortas of cholesterol fed rabbits: Relationship to lesion severity. Atherosclerosis 1997;130:61-70.
40. Godin D, Ivan E, Johnson C, Magid R, Galis ZS. Remodeling of carotid artery is associated with increased expression of matrix metalloproteinases in mouse blood flow cessation model. Circulation 2000;102:2861-6.
41. Carrell TW, Burnand KG, Wells GM, Clements JM, Smith A. Stromelysin-1 (matrix metalloproteinase-3) and tissue inhibitor of metalloproteinase-3 are overexpressed in the wall of abdominal aortic aneurysms. Circulation 2002;105:477-82.
42. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-503.
43. Sukhova GK, Schonbeck U, Rabkin E, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999;99:2503-9.
44. Halpert I, Sires UI, Roby JD, et al. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci U S A 1996;93:9748-53.
45. Herman MP, Sukhova GK, Libby P, et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: A novel collagenolytic pathway suggested by transcriptional profiling. Circulation 2001;104:1899-904.
46. Henney AM, Wakeley PR, Davies MJ, et al. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci U S A 1991;88:8154-8.
47. Schonbeck U, Mach F, Sukhova GK, et al. Expression of stromelysin-3 in atherosclerotic lesions: Regulation via CD40-CD40 ligand signaling in vitro and in vivo. J Exp Med 1999;189:843-53.
48. Galis ZS, Sukhova GK, Kranzhofer R, Clark S, Libby P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci U S A 1995;92:402-6.
49. Jenkins GM, Crow MT, Bilato C, et al. Increased expression of membrane-type matrix metalloproteinase and preferential localization of matrix metalloproteinase-2 to the neointima of balloon-injured rat carotid arteries. Circulation 1998;97:82-90.
50. Rekhter MD, Hicks GW, Brammer DW, et al. Hypercholesterolemia causes mechanical weakening of rabbit atheroma: Local collagen loss as a prerequisite of plaque rupture. Circ Res 2000;86:101-8.